{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:26:25Z","timestamp":1707524785851},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,29]]},"DOI":"10.7759\/cureus.30833","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T12:23:22Z","timestamp":1667046202000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Inhalational Aztreonam Lysine in Lower Airway Infections in Cystic Fibrosis: An Updated Literature Review"],"prefix":"10.7759","author":[{"given":"Mehwish","family":"Zeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujan","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ijeoma A","family":"Toulassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varshitha","family":"Kondapaneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Cancarevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cystic Fibrosis Foundation. 2018 Patient Registry. Annual data report. (2018). Accessed: August 14, 2020: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson J","year":"2002","unstructured":"Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002, 34:91-100. 10.1002\/ppul.10127","journal-title":"Pediatr Pulmonol"},{"key":"ref3","unstructured":"Patient registry 2020 annual data report. (2020). Accessed. August 27, 2022: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/318075","article-title":"Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns JL","year":"2001","unstructured":"Burns JL, Gibson RL, McNamara S, et al.. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001, 183:444-52. 10.1086\/318075","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis","volume":"293","author":"Li Z","year":"2005","unstructured":"Li Z, Kosorok MR, Farrell PM, et al.. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005, 293:581-8. 10.1001\/jama.293.5.581","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/35037627","article-title":"Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms","volume":"407","author":"Singh PK","year":"2000","unstructured":"Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000, 407:762-4. 10.1038\/35037627","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart GZ","year":"2009","unstructured":"Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009, 135:1223-32. 10.1378\/chest.08-1421","journal-title":"Chest"},{"key":"ref8","unstructured":"CAYSTON\u00ae (aztreonam for inhalation solution), for oral inhalation use. (2019). Accessed. August 27, 2022: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/respiratory\/cayston\/cayston_pi.pdf."},{"key":"ref9","unstructured":"CAYSTON\u00ae (aztreonam) inhalation solution label. (2010). Accessed. September 21, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050814s007lbl.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson RL","year":"2006","unstructured":"Gibson RL, Retsch-Bogart GZ, Oermann C, et al.. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006, 41:656-65. 10.1002\/ppul.20429","journal-title":"Pediatr Pulmonol"},{"key":"ref11","article-title":"Cystic Fibrosis: Antibiotic Therapy for Chronic Pulmonary Infection","author":"Simon RH","year":"2020","unstructured":"Simon RH, Mallory GB, Hoppin AG. Cystic Fibrosis: Antibiotic Therapy for Chronic Pulmonary Infection. Post TW (ed): UpToDate, Waltham; 2020."},{"key":"ref12","unstructured":"Study of aztreonam for inhalation in children with cystic fibrosis and new infection of the airways by Pseudomonas aeruginosa bacteria (Alpine 2). (2017). Accessed. August 27, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03219164."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1023\/a:1022037320039","article-title":"Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients","volume":"12","author":"Henry B","year":"2003","unstructured":"Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res. 2003, 12:63-76. 10.1023\/a:1022037320039","journal-title":"Qual Life Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann CM","year":"2010","unstructured":"Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010, 45:1121-34. 10.1002\/ppul.21301","journal-title":"Pediatr Pulmonol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2019-BTSabstracts2019.26","article-title":"S20 inhaled aztreonam lysine recovers lung function and improves quality of life in acute pulmonary exacerbations of cystic fibrosis","volume":"74","author":"Frost F","year":"2019","unstructured":"Frost F, Fothergill J, Winstanley C, Nazareth D, Walshaw MJ. S20 inhaled aztreonam lysine recovers lung function and improves quality of life in acute pulmonary exacerbations of cystic fibrosis. Thorax. 2019, 74:13-14. 10.1136\/thorax-2019-BTSabstracts2019.26","journal-title":"Thorax"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy KS","year":"2008","unstructured":"McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008, 178:921-8. 10.1164\/rccm.200712-1804OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa","volume":"10","author":"Wainwright CE","year":"2011","unstructured":"Wainwright CE, Quittner AL, Geller DE, et al.. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros. 2011, 10:234-42. 10.1016\/j.jcf.2011.02.007","journal-title":"J Cyst Fibros"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-1993(09)60112-0","article-title":"Efficacy of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)","volume":"8","author":"McCoy KS","year":"2009","unstructured":"McCoy KS, Retsch-Bogart GZ, Gibson RL, et al.. Efficacy of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA). J Cyst Fibros. 2009, 8:28. 10.1016\/s1569-1993(09)60112-0","journal-title":"J Cyst Fibros"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.06.003","article-title":"Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study","volume":"14","author":"Tiddens HA","year":"2015","unstructured":"Tiddens HA, De Boeck K, Clancy JP, et al.. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study. J Cyst Fibros. 2015, 14:111-9. 10.1016\/j.jcf.2014.06.003","journal-title":"J Cyst Fibros"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s1569-1993(17)30340-5","article-title":"EPS7.10 Clinical benefit of continuous nebulised aztreonam lysine for Inhalation (AZLI) in adults with cystic fibrosis - a retrospective cohort study","volume":"16","author":"Morton R","year":"2017","unstructured":"Morton R, Doe S, Banya W, et al.. EPS7.10 Clinical benefit of continuous nebulised aztreonam lysine for Inhalation (AZLI) in adults with cystic fibrosis - a retrospective cohort study. J Cyst Fibros. 2017, 16:55. 10.1016\/s1569-1993(17)30340-5","journal-title":"J Cyst Fibros"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.02.006","article-title":"A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis","volume":"16","author":"Plant BJ","year":"2017","unstructured":"Plant BJ, Downey DG, Eustace JA, et al.. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. J Cyst Fibros. 2017, 16:695-701. 10.1016\/j.jcf.2017.02.006","journal-title":"J Cyst Fibros"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2016.05.001","article-title":"Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis","volume":"15","author":"Flume PA","year":"2016","unstructured":"Flume PA, Clancy JP, Retsch-Bogart GZ, et al.. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016, 15:809-15. 10.1016\/j.jcf.2016.05.001","journal-title":"J Cyst Fibros"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A1188","article-title":"Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF)","volume":"179","author":"Montgomery AB","year":"2009","unstructured":"Montgomery AB, Lewis S, Higuchi K, Marshall B, Oermann C. Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF). Am J Respir Crit Care Med. 2009, 179:1188. 10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A1188","journal-title":"Am J Respir Crit Care Med"},{"key":"ref24","unstructured":"Safety of Azli in children with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa in the lower airways (PALS). (2011). Accessed. August 27, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01404234."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/44183-role-of-inhalational-aztreonam-lysine-in-lower-airway-infections-in-cystic-fibrosis-an-updated-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:46Z","timestamp":1707507766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/44183-role-of-inhalational-aztreonam-lysine-in-lower-airway-infections-in-cystic-fibrosis-an-updated-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.30833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}